FDA Approves Viral Therapy Plus Nivolumab
Accelerated approval is based on objective response rate and duration of response in advanced melanoma, with postapproval trials required to confirm clinical benefit.
By
Kathryn Wighton
August 7, 2026
Clinical Scorecard: FDA Approves Viral Therapy Plus Nivolumab
At a Glance
Category Detail
Condition Unresectable Advanced Cutaneous Melanoma Key Mechanisms Combination of viral therapy (vusolimogene oderparepvec-wtpg) and nivolumab targeting immune response. Target Population Adults with unresectable advanced melanoma whose disease progressed on prior PD-1-blocking therapy. Care Setting Oncology
Key Highlights
Accelerated approval granted by FDA based on IGNYTE trial results. Objective response rate of 24.2% observed in the trial. Median duration of response was 14.1 months. Postapproval trials required to verify clinical benefit. Warnings include risks of herpetic infection and immune-mediated events. Guideline-Based Recommendations
Diagnosis
Diagnosis of unresectable advanced melanoma confirmed through clinical evaluation. Management
Administer vusolimogene oderparepvec-wtpg intratumorally every 2 weeks for 8 doses. Nivolumab administered intravenously starting at week 3. Monitoring & Follow-up
Monitor for adverse reactions including fatigue, infections, and immune-mediated events. Risks
Accidental exposure, herpetic infection or reactivation, injection procedure complications. Patient & Prescribing Data
Adults with stage IIIB, IIIC, or IV unresectable advanced melanoma.
Recommended dosage is 1 mL per cm of largest tumor dimension, up to 10 mL total.
Clinical Best Practices
Ensure proper administration technique for intratumoral injections. Educate patients on potential adverse reactions and monitoring requirements. Related Resources & Content
